Although most current studies have not disclosed data for the liver metastasis subgroup, overall, the data from these prospective clinical trials demonstrate the safety and efficacy of anti-CTLA-4 + anti-PD-1 in the treatment of metastatic NSCLC, as well as support its use in patients with liver metastasis. Here, CTLA4 is linked to non-small cell lung carcinoma.